ACA
IDXX icon

Aptus Capital Advisors’s Idexx Laboratories IDXX Stock Holding History

Aptus Capital Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.26M Sell
9,994
-103
-1% -$57.8K 0.04% 354
2026
Q1 		$5.67M Sell
10,097
-2,123
-17% -$1.36M 0.04% 318
2025
Q4 		$8.27M Buy
12,220
+633
+5% +$431K 0.06% 242
2025
Q3 		$7.4M Sell
11,587
-1,205
-9% -$731K 0.05% 256
2025
Q2 		$6.86M Buy
12,792
+2,816
+28% +$1.35M 0.06% 250
2025
Q1 		$4.19M Buy
9,976
+14
+0.1% +$6.08K 0.04% 303
2024
Q4 		$4.12M Buy
9,962
+9,333
+1,484% +$4.09M 0.04% 299
2024
Q3 		$318K Buy
629
+102
+19% +$49.6K ﹤0.01% 648
2024
Q2 		$257K Buy
527
+66
+14% +$33.1K ﹤0.01% 659
2024
Q1 		$249K Buy
461
+77
+20% +$42.1K ﹤0.01% 680
2023
Q4 		$213K Buy
+384
New +$180K 0.01% 538

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Aptus Capital Advisors's IDXX Position: Q2 2026 in Review

Aptus Capital Advisors reduced its Idexx Laboratories (IDXX) stake by 1% in Q2 2026, selling an estimated $57.8K and leaving 9,994 shares worth $5.26M. The position accounts for 0.04% of the portfolio, ranked #354.

Aptus Capital Advisors first reported a position in IDXX in Q4 2023 and has held it in 11 quarters since. The position peaked at $8.27M in Q4 2025. 1,302 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Aptus Capital Advisors held 9,994 shares of Idexx Laboratories worth $5.26M as of Q2 2026.
  • Aptus Capital Advisors sold 103 Idexx Laboratories shares in Q2 2026, an estimated $57.8K.
  • Idexx Laboratories made up 0.04% of Aptus Capital Advisors's portfolio in Q2 2026, its #354 holding.
  • Aptus Capital Advisors first reported a position in Idexx Laboratories in Q4 2023 and has held it in 11 quarters since.
  • Aptus Capital Advisors's Idexx Laboratories position peaked at $8.27M in Q4 2025.
  • 1,302 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.